Last reviewed · How we verify

sara nabil — Portfolio Competitive Intelligence Brief

sara nabil pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
OraVerse Injectable Product OraVerse Injectable Product phase 3 Alpha-adrenergic antagonist Alpha-1 and alpha-2 adrenergic receptors Dental/Local Anesthesia

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ocuphire Pharma, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for sara nabil:

Cite this brief

Drug Landscape (2026). sara nabil — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sara-nabil. Accessed 2026-05-14.

Related